Newsmakers

NexTech AR Solutions (OTC: NEXCF) to Webcast Live at VirtualInvestorConferences.com February 20th

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com NEW YORK, and TORONTO, Feb. 17, 2020  — NexTech AR Solutions (otcqb:NEXCF) (NTAR)(N29), based in Toronto Canada, today announced that […]

Healthcare

CytoDyn (OTC: CYDY) Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA

VANCOUVER, Washington, Feb. 14, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today continued positive […]

Newsmakers

NexTech (OTC: NEXCF) Receives New 2020 Contract from Walther Arms Inc., Manufacturer of James Bond’s PPK

NEW YORK and TORONTO, Feb. 12, 2020  — NexTech AR Solutions (NexTech) (otcqb:NEXCF) (NTAR)(N29), the leader in augmented reality for e-commerce and AR learning applications, has received a new order from Walther Arms, most famous as the […]

Newsmakers

Former EVP, Head of Universal Music Group and Brands-USA Joins Advisory Board of Imagination Park Technologies (OTC: IPNFF)

Vancouver, CANADA – – February 11 , 2020 – Imagination Park Technologies Inc. (CSE: IP)(OTC: IPNFF) today announced that Mike Tunnicliffe has joined the Company as a Senior Advisor to the CEO. Mr. Tunnicliffe previously served […]

Newsmakers

CytoDyn (OTC: CYDY) Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers

VANCOUVER, Washington, Feb. 06, 2020– CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it […]

Healthcare

CytoDyn (OTC: CYDY) to Hold Investment Community Conference Call on February 6, 2020

VANCOUVER, Washington, Feb. 03, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader […]

Healthcare

CytoDyn (OTC: CYDY) Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition

Third patient data supports leronlimab (PRO 140) as a potential treatment option for metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). Patient CTC dropped to zero after 2 weeks of leronlimab treatment, same […]